A naukri.com initiative
Bioengineer
1w
391
Image Credit: Bioengineer
Abexinostat Shows Promise for B Cell Lymphoma
- Abexinostat, a novel pan-histone deacetylase inhibitor, shows promise as a therapeutic agent for relapsed or refractory B cell non-Hodgkin lymphoma (NHL), based on a Phase 1 clinical trial in Chinese patients.
- Histone deacetylase inhibitors (HDACis) like abexinostat alter gene expression by modulating chromatin structure, promoting tumor suppressor gene activation and cell death pathways in malignant cells.
- A Phase 1 trial in Chinese patients assessed the safety, pharmacokinetics, and efficacy of abexinostat, administered on an intermittent dosing schedule to optimize antitumor activity and minimize toxicities.
- The trial revealed a well-tolerated profile of abexinostat with no dose-limiting toxicities, even at the highest dose, and established the recommended Phase 2 dose at 80 mg twice daily.
- Pharmacokinetic analyses showed rapid systemic availability, favorable absorption and elimination characteristics, and dose-proportional kinetics for abexinostat.
- Efficacy data indicated a 40% objective response rate, with promising outcomes in follicular lymphoma patients, suggesting abexinostat's potential in a treatment-refractory population.
- The study's findings support the rationale of an intermittent dosing schedule for abexinostat, balancing efficacy with reduced cumulative toxicity and aligning with targeted cancer therapy trends.
- Further clinical development through larger Phase 2 and 3 trials is warranted to validate efficacy signals, determine patient subgroups that benefit most, and explore combination strategies with other treatments.
- The research highlights the importance of integrating early pharmacokinetic assessments in drug development, aiming to optimize dosing protocols and accelerate the transition from laboratory to clinical practice.
- Abexinostat's potential in relapsed or refractory B cell NHL offers hope for improved survival and quality of life, presenting a promising addition to precision oncology approaches challenging traditional chemotherapy paradigms.
- Collaborative global efforts and comprehensive clinical investigations will be crucial to confirming these findings and potentially ushering in a new era of lymphoma treatment through epigenetic modulation and personalized therapy.
Read Full Article
23 Likes
For uninterrupted reading, download the app